• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液系统恶性肿瘤患者发热性中性粒细胞减少症生存结局的相关因素

Factors Associated with Survival Outcomes of Febrile Neutropenia in Hematologic Malignancy Patients.

作者信息

Weerasubpong Borworn, Makruasi Nisa, Linasmita Patcharasarn, Rattanamongkolgul Suthee

出版信息

J Med Assoc Thai. 2016 Nov;99 Suppl 8:S53-S62.

PMID:29901912
Abstract

BACKGROUND

Febrile neutropenia (FN) is a common, life-threatening complication of hematologic malignancy patients who receive chemotherapy. The assessment of the epidemiology and related factors are necessary to improve survival outcomes of FN.

OBJECTIVE

To determine the epidemiology of FN and investigate the factors that are associated with outcomes of FN.

MATERIAL AND METHOD

This study is a retrospective cohort study. Medical records between 2012 and 2014 of fifty FN patients of the Her Royal Highness (HRH) Princess Maha Chakri Sirindhorn Medical Center were reviewed.

RESULTS

Of the 50 episodes with FN, the median age was 35.5 years (range from 15 to 81 years), and 39 patients (78%) were younger than 60 years of age. Thirty-three patients (66%) were treated with the first-line chemotherapy. Source of infections could not be identified in 58% of patients. For patients with a definite source of infection, 14% were lower respiratory tract infections. Gram-negative bacteria were more common than gram-positive organisms as found in blood cultures. The multivariate analysis has confirmed a significant association with no weight loss greater than 5% within 1 month (p<0.05), no blood loss requiring intravenous fluid (p = 0.01), and low Acute Physiology and Chronic Health Evaluation (APACHE) II score (p = 0.01) associated with survival outcomes of FN. The overall mortality was 28%.

CONCLUSION

There was a high mortality rate in neutropenic patients with fever. The no significant weight loss, no blood loss requiring intravenous fluid, and low APACHE II score at the time of diagnosed FN were found to be associated factors with survival outcomes.

摘要

背景

发热性中性粒细胞减少症(FN)是接受化疗的血液系统恶性肿瘤患者常见的、危及生命的并发症。评估其流行病学及相关因素对于改善FN患者的生存结局很有必要。

目的

确定FN的流行病学特征,并调查与FN结局相关的因素。

材料与方法

本研究为回顾性队列研究。回顾了诗琳通公主殿下医疗中心2012年至2014年期间50例FN患者的病历。

结果

在50例FN病例中,中位年龄为35.5岁(范围15至81岁),39例患者(78%)年龄小于60岁。33例患者(66%)接受一线化疗。58%的患者感染源不明。对于有明确感染源的患者,14%为下呼吸道感染。血培养结果显示革兰阴性菌比革兰阳性菌更常见。多因素分析证实,1个月内体重减轻不超过5%(p<0.05)、无需静脉补液的失血情况(p = 0.01)以及急性生理与慢性健康状况评分系统(APACHE)II评分较低(p = 0.01)与FN的生存结局相关。总体死亡率为28%。

结论

发热性中性粒细胞减少症患者死亡率较高。确诊FN时体重无明显减轻、无需静脉补液的失血情况以及APACHE II评分较低是与生存结局相关的因素。

相似文献

1
Factors Associated with Survival Outcomes of Febrile Neutropenia in Hematologic Malignancy Patients.血液系统恶性肿瘤患者发热性中性粒细胞减少症生存结局的相关因素
J Med Assoc Thai. 2016 Nov;99 Suppl 8:S53-S62.
2
Incidence, Risk Factors, and Outcomes of Febrile Neutropenia in Thai Hematologic Malignancy Patients Receiving Chemotherapy: A 6-year Retrospective Cohort Study.泰国接受化疗的血液系统恶性肿瘤患者发热性中性粒细胞减少症的发病率、危险因素及结局:一项6年回顾性队列研究
Asian Pac J Cancer Prev. 2015;16(14):5945-50. doi: 10.7314/apjcp.2015.16.14.5945.
3
Febrile neutropenia in hematologic malignancies.血液恶性肿瘤患者的中性粒细胞减少伴发热。
Curr Hematol Malig Rep. 2013 Dec;8(4):370-8. doi: 10.1007/s11899-013-0171-4.
4
Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients.血浆可溶性髓系细胞触发受体-1水平是血液系统恶性肿瘤患者严重发热性中性粒细胞减少症的早期诊断标志物。
BMC Infect Dis. 2017 Jan 5;17(1):27. doi: 10.1186/s12879-016-2116-8.
5
Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia.成人血液系统恶性肿瘤伴发热性中性粒细胞减少症患者使用抗生素的时间与临床结局的关联
J Oncol Pharm Pract. 2017 Jun;23(4):278-283. doi: 10.1177/1078155216687150. Epub 2017 Jan 11.
6
[Epidemiology of febrile neutropenia in adult patients with hematologic neoplasms in a period of 26 months in Hospital Pablo Tobón Uribe, Colombia].[哥伦比亚巴勃罗·托本·乌里韦医院26个月期间血液系统肿瘤成年患者发热性中性粒细胞减少症的流行病学]
Rev Chilena Infectol. 2013 Apr;30(2):195-201. doi: 10.4067/S0716-10182013000200010.
7
Clinical significance of repeat blood cultures during febrile neutropenia in adult acute myeloid leukaemia patients undergoing intensive chemotherapy.成人急性髓系白血病患者强化化疗后中性粒细胞减少性发热时重复血培养的临床意义。
Infect Dis (Lond). 2017 Oct;49(10):748-757. doi: 10.1080/23744235.2017.1340665. Epub 2017 Jun 20.
8
Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.血液系统恶性肿瘤患者发热性中性粒细胞减少症中的继发感染:不止是又一次发热性中性粒细胞减少发作。
Turk J Haematol. 2015 Sep;32(3):243-50. doi: 10.4274/tjh.2013.0422.
9
Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients.发热性中性粒细胞减少症发作时的尿液培养很少会影响无症状成年癌症患者的抗生素管理。
Support Care Cancer. 2019 Apr;27(4):1223-1227. doi: 10.1007/s00520-018-4476-7. Epub 2018 Sep 27.
10
Differential risk of severe infection in febrile neutropenia among children with blood cancer or solid tumor.发热性中性粒细胞减少症中儿童血液肿瘤或实体瘤患者严重感染的差异风险。
J Infect. 2019 Aug;79(2):95-100. doi: 10.1016/j.jinf.2019.06.008. Epub 2019 Jun 19.

引用本文的文献

1
Clinical Outcome of Febrile Neutropenia and Associated Factors Among Adult Patients with Cancer Treated at Ethiopian Oncology Centers: A Retrospective Observational Study.埃塞俄比亚肿瘤中心接受治疗的成年癌症患者发热性中性粒细胞减少症的临床结局及相关因素:一项回顾性观察研究
Oncol Ther. 2025 Jul 16. doi: 10.1007/s40487-025-00356-0.
2
Mean Platelet Volume-to-Albumin Ratio as a Predictor of Mortality in Patients with Febrile Neutropenia: An Observational Study.平均血小板体积与白蛋白比值作为发热性中性粒细胞减少症患者死亡率的预测指标:一项观察性研究
Medicina (Kaunas). 2025 Mar 26;61(4):601. doi: 10.3390/medicina61040601.
3
PCT-to-albumin ratio and CRP-to-albumin ratio as predictors of febrile neutropenia complications: a prospective observational trial.
降钙素原与白蛋白比值及C反应蛋白与白蛋白比值作为发热性中性粒细胞减少症并发症预测指标的前瞻性观察性试验
Support Care Cancer. 2025 Mar 10;33(4):262. doi: 10.1007/s00520-025-09329-5.
4
Serum Albumin as a Prognostic Biomarker for Febrile Neutropenia Outcome and Complications: A Prospective Observational Trial.血清白蛋白作为发热性中性粒细胞减少症结局和并发症的预后生物标志物:一项前瞻性观察性试验。
Clin Med Insights Oncol. 2024 Sep 24;18:11795549241281330. doi: 10.1177/11795549241281330. eCollection 2024.
5
All-Cause Mortality and Its Predictors in Haemato-Oncology Patients with Febrile Neutropenia.血液肿瘤伴发热性中性粒细胞减少症患者的全因死亡率及其预测因素
J Clin Med. 2023 Aug 29;12(17):5635. doi: 10.3390/jcm12175635.
6
Mortality-associated clinical risk factors in patients with febrile neutropenia: A retrospective study.发热性中性粒细胞减少症患者的死亡相关临床危险因素:一项回顾性研究。
IJID Reg. 2021 Sep 20;1:5-11. doi: 10.1016/j.ijregi.2021.09.002. eCollection 2021 Dec.